Karyopharm Therapeutics | KPTI - أصول متداولة





أصول متداولة تغيير تاريخ
AbbVie USD 29.06B 523M 2025-12
Abbott USD 25.51B 488M 2026-03
Amgen USD 31.48B 2.42B 2026-03
AstraZeneca USD 29.61B 890M 2026-03
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
Incyte USD 5.48B 460.36M 2026-03
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
Merck USD 35.02B 8.5B 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Novartis USD 26.61B 3.85B 2026-03
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 42.82B 76M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Takeda JPY 3.12T 195.82B 2025-12
Tectonic Therapeutic USD 257.36M 15.88M 2025-12
TG Therapeutics USD 630.76M 31M 2025-12
Ultragenyx Pharmaceutical USD 951M 307.79M 2025-12
Xencor USD 599.82M 81.38M 2025-12